All In Biotech

NDA 022399 · Azurity

Horizant

Gabapentin Enacarbil · Oral

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Apr 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Apr 6, 2011

Approved uses

3

Original approval plus efficacy supplements

Registered trials

501

111 Phase 3, 25 recruiting

FAERS reports

2,844

1,590 serious, 700 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 28, 2025.

HORIZANT is indicated for: treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults. ( 1.1 ) management of postherpetic neuralgia (PHN) in adults. ( 1.2 ) 1.1 Treatment of Restless Legs Syndrome HORIZANT ® is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults. HORIZANT is not recommended for patients who are required to sleep during the daytime and remain awake at night. 1.2 Management of Postherpetic Neuralgia HORIZANT is indicated for the management of postherpetic neuralgia (PHN) in adults.

Mechanism: Gabapentin enacarbil is a prodrug of gabapentin and, accordingly, its therapeutic effects in RLS and PHN are attributable to gabapentin. The precise mechanism by which gabapentin is efficacious in RLS and PHN is unknown. The mechanism of action by which gabapentin is efficacious in PHN is unknown but in animal models of analgesia, gabapentin prevents allodynia (pain-related behavior in response to a normally innocuous stimulus) and hyperalgesia (exaggerated response to painful stimuli). Gabapentin prevents pain-related responses in several models of neuropathic pain in rats and mice (e.g.,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • HORIZANT · GABAPENTIN ENACARBIL 600MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • HORIZANT · GABAPENTIN ENACARBIL 300MG · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Gabapentin Enacarbil" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • toxicity to various agents594
  • completed suicide277
  • drug ineffective217
  • off label use187
  • drug abuse138
  • dizziness126
  • somnolence125
  • nausea122
  • insomnia116
  • cardio-respiratory arrest110
  • headache110
  • fatigue99

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201132
2012104
201359
201435
201592
2016206
2017340
2018352
2019442
2020308
2021212
2022293
2023119
202489
2025100
202661

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Horizant (Gabapentin Enacarbil)

2024 spending

$31.8M

Beneficiaries

5,984

28,883 claims

Per beneficiary

$5,320

$16.69 per unit

View as table
YearSpending
2020$29,899,246
2021$32,575,765
2022$33,507,494
2023$32,997,342
2024$31,837,117

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 48 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.